*Bidvest expects PIC to reject offer. *Bidvest offered 52 rand per share, or $515 mln. JOHANNESBURG, March 2- The chief executive of South Africa's Bidvest Group said his $515 million buyout offer for Adcock Ingram is likely to be rejected by a major shareholder, meaning the industrial conglomerate could end up with less than 100 percent.» Read More
P&G has been one of the great growth companies of all times but quite frankly it has stumbled over the past couple of years under the current CEO's leadership, said William Ackman, Pershing Square Capital Management founder & CEO, discussing the problems at Procter & Gamble.
In this excerpt from a "Squawk Box" interview on October 2, 2012, Pershing Square's Bill Ackman said he had bought some stock and expressed his concerns about the company to its Board.
In court documents that lawyers for Bain Capital sought to keep secret, the company and other leading private equity firms are depicted as unofficial partners in a bid-rigging conspiracy aimed at holding down the prices of businesses they were seeking to buy, The New York Times reports.
Dinakar Singh, TPG-Axon Capital CEO, discusses the best way to play the health care space.
Dinakar Singh, TPG-Axon Capital CEO, discusses the best way to trade financials after the banking crisis.
"Ultimately, I don't think lower rates make that much difference anymore," says Dinakar Singh, TPG-Axon Capital CEO, sharing his thoughts on additional Fed easing.
The co-founder of the trailblazing private-equity firm Kohlberg Kravis Roberts is actively involved in managing the firm famous for its leveraged buyout of RJR Nabisco 25 years ago.
CNBC's David Faber reports the latest details on GlaxoSmithKline's takeover bid for Human Genome Science.
Here are five companies that could be bought, according to analyst Ken Hackel of CT Capital, best known for his book, “Security Valuation and Risk Analysis.”
CNBC's Scott Cohn reports on what the Justice Department calls the biggest health care fraud settlement in U.S. history; and CNBC's Seema Mody reports on the details of Bristol-Myers' plans to buy Amylin.
CNBC's Kayla Tausche reports Grupo Modelo has confirmed it is in talks on expanding its relationship with Anheuser-Busch.
CNBC's David Faber speaks to activist investor Carl Icahn regarding how much cash he has available to invest and whether Chesapeake Energy is undervalued.
Human Genome Sciences rejected the $2.6 billion unsolicited takeover bid from GlaxoSmithKline, reports CNBC's Herb Greenberg.
CNBC's Kayla Tausche reports on Illumina playing offense against Roche's hostile takeover bid, and the FMHR crew share their final trades of the hour.
CNBC's David Faber reports the latest details on Illumina's recommendation to shareholders to reject Roche's takeover offer.
Mad Money host Jim Cramer shares his final thoughts on the future of tech giants, Research in Motion and Yahoo.
The Fast Money traders weigh in on how to play unusual options activity in Avon's shares on Monday.
CNBC's Brian Shactman breaks down today's big movers including two downgrades at Stifel Nicolaus, and Avon's rejection of a takeover bid from Coty.
Karen Finerman, Metropolitan Capital Advisors, and Fast Money trader, provides insight on what's next for Illumina, on the heels its recent rejection of Roche's offer.
Cramer ticks off the many winning trades today.